Skip to main content
. Author manuscript; available in PMC: 2014 Mar 1.
Published in final edited form as: Int J Neuropsychopharmacol. 2012 Jun 7;16(2):301–311. doi: 10.1017/S1461145712000545

Table 1.

Impact of ketamine infusion on sleep (n=30)

Variables BSL (1)
Mean(±s.e.m.)
Infusion (2)
Mean (±s.e.m.)
Recovery (3)
Mean (±s.e.m.)
ANOVA
p value for comparison a
df F p 1 vs.2 2 vs.3 1 vs. 3
TST, min 368.10 (10.4) 392.97 (7.63) 395.00 (8.35) 2, 58 5.5 <0.01 0.02 1.00 0.01
S1, % 9.46 (0.93) 7.79 (0.71) 8.84 (0.81) 2, 58 3.3 <0.05 0.03 0.33 1.00
S2, % 62.11(1.80) 58.32 (2.14) 59.63 (1.98) 2, 58 4.74 0.01 0.001 0.14 0.87
SWS, % 3.52 (0.70) 4.73 (0.99) 4.40 (0.92) 2, 58 16.6 0.01 0.04 1.00 0.20
REM, % 25.28 (1.30) 29.51 (1.59) 27.72 (1.28) 2, 58 5.9 <0.01 0.001 0.38 0.11
SOL, min 24.11 (3.7) 15.56 (2.26) 18.23 (3.1) 2, 58 4.1 <0.05 0.01 1.00 0.13
REML, min 78.71 (6.9) 61.23 (6.6) 66.71 (6.5) 2, 58 4.6 0.01 0.01 1.00 0.13
Waking, % rec 17.37 (2.16) 13.48 (1.43) 13.25 (1.61) 2, 58 3.5 <0.05 0.06 1.00 0.04

BSL, Baseline; ANOVA, analysis of variance ; TST, total sleep time; S1, non-rapid eye movement (NREM) stage 1 (% of TST); S2, NREM stage 2 (% of TST); SWS, slow wave sleep ; REM, stage REM (% of TST); SOL, sleep onset latency ; REML, REM sleep latency ; rec, recording time.

a

Post-hoc t tests. p values are expressed with Bonferroni’s correction where p<0.05 is considered significant.